Loading
A phase 2 trial in pancreatic cancer, run by University of California, San Diego, now recruiting.
Cemiplimab Plus Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma is a phase 2, interventional study registered as NCT06790602 by University of California, San Diego, with a registry enrolment figure of 43 participants, started 2026-05-06 and due to reach its primary completion in 2028-07. Interventions recorded: Cemiplimab Plus Gemcitabine. Conditions listed: Pancreatic Ductal Adenocarcinoma (mPDAC). Primary outcome: Overall survival. Pancreatic eligibility wording from the registry: "Histologically or cytologically confirmed pancreatic ductal adenocarcinoma". Sites: United States. No results are recorded here; the registry entry is the source.
Shares Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.
Shares Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.
Shares Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.
Shares Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.
Shares Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.
Shares Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.
Shares Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.
Shares Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.